JNJ's Talvey Cuts Mortality in Earlier Myeloma Line (JNJ)

Johnson & Johnson released Phase 3 data Wednesday showing its bispecific antibody Talvey reduced mortality risk in patients with multiple myeloma who had received one to three prior lines of therapy. The results position the drug for an earlier-line approval and a bigger slice of a market worth about $30 billion globally.

Talvey targets the BCMA protein on myeloma cells and the CD3 receptor on T cells, pulling the immune system into the fight. J&J already sells it under the brand name Tecvayli for patients who have exhausted four or more lines of treatment. The new trial tested it in an earlier setting, where the patient pool is larger and the competition thinner.

The drug generated $1.2 billion in 2024 sales, J&J reported in its annual filing. An earlier-line go-ahead would open reimbursement at an earlier stage of the disease, potentially doubling or tripling the addressable patient population. Analysts at several firms have flagged Talvey as a $4 billion to $5 billion peak-sales candidate if it wins second-line use.

The readout also matters for J&J's broader oncology strategy. The company owns Carvykti, a CAR-T therapy that competes in the same space but requires a multi-week manufacturing process. Talvey is an off-the-shelf product, given as a weekly injection. That difference could tilt the prescribing decision toward Talvey in less acute patients, while reserving Carvykti for the sickest.

Multiple myeloma is the second most common blood cancer, and the treatment landscape has shifted fast. Bristol Myers Squibb sells a CAR-T called Abecma. AbbVie and Regeneron have bispecifics in late-stage testing. J&J's edge is depth: it has both a CAR-T and a bispecific, and the data now show its bispecific works earlier than its rivals' alternatives.

The Phase 3 trial enrolled 380 patients across 20 countries. J&J said the results meet all primary and secondary endpoints, and the company plans to submit the data to regulators this year. The FDA has already granted Talvey breakthrough therapy designation, which can shorten the review cycle.

Talvey carries known side effects – cytokine release syndrome and neurotoxicity – but the rates in the earlier-line trial were consistent with what J&J reported in later-line studies, the company said. No new safety signals appeared.

For JNJ shareholders, the next concrete catalyst is the regulatory filing. A typical FDA review for a priority drug runs six to eight months. If the submission happens by mid-year, a decision could come before the end of 2025. That timeline would let J&J start booking earlier-line revenue in 2026.

Talvey is already approved for fourth-line multiple myeloma under the brand name Tecvayli. An earlier-line approval would extend its reach to a population that is larger and lives longer with the disease.

Check the JNJ stock page for the latest price moves and analyst targets.